Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine

Annals of Nuclear Medicine
Seigo KinuyaHiroshi Kawamoto

Abstract

Since the 1980s when clinical therapeutic trials were initiated, (131)I-MIBG radiotherapy has been used in foreign countries for unresectable neuroendocrine tumors including malignant pheochromocytomas and neuroblastomas. In Japan, (131)I-MIBG radiotherapy has not been approved by the Ministry of Health, Labour and Welfare; however, personally imported (131)I-MIBG is now available for therapeutic purposes in a limited number of institutions. These updated draft guidelines aim to provide useful information concerning (131)I-MIBG radiotherapy, to help prevent side effects and protect physicians, nurses, other health care professionals, patients and their families from radiation exposure. The committee has also provided appendices on topics such as practical guidance for attending physicians, patient management, and referring physicians.

References

Jan 1, 1987·Medical and Pediatric Oncology·P A VoûteA Green
May 1, 1994·Annals of Nuclear Medicine·H SakaharaJ Konishi
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P A VoûteH Van Gennip
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J De KrakerP A Voûte
Nov 1, 1994·Annals of Nuclear Medicine·Y Nakabeppu, M Nakajo
Sep 1, 1994·Nuclear Medicine Communications·C A HoefnagelP A Voûte
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B G TaalJ H Beijnen
Jun 2, 1998·Medical and Pediatric Oncology·R MastrangeloS Mastrangelo
Sep 18, 1999·Lancet·J F Chatal, C A Hoefnagel
Jan 6, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B G TaalM Rutgers
May 8, 2001·Nuclear Medicine Communications·M A MonsieursR A Dierckx
Jun 9, 2001·Endocrine-related Cancer·F OrlandiA Angeli
Nov 30, 2002·European Journal of Nuclear Medicine and Molecular Imaging·Myriam MonsieursHubert Thierens
May 2, 2003·European Journal of Nuclear Medicine and Molecular Imaging
Jul 9, 2003·Journal of Pediatric Hematology/oncology·Brian WeissKatherine K Matthay
Jul 14, 2004·European Journal of Endocrinology·Gregory KaltsasAshley B Grossman
Nov 15, 2006·Annals of the New York Academy of Sciences·Paul A FitzgeraldKatherine K Matthay
Nov 15, 2006·Annals of the New York Academy of Sciences·James C SissonNazanene H Esfandiari
Mar 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine K MatthayJohn M Maris
Feb 16, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Francesco GiammarileUNKNOWN EANM

❮ Previous
Next ❯

Citations

Jan 20, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Yasuhiro OhshimaNoriko S Ishioka
Aug 14, 2018·Nuclear Medicine and Molecular Imaging·Daiki Kayano, Seigo Kinuya
Mar 5, 2019·Nuclear Medicine and Molecular Imaging·Seigo Kinuya
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shozo OkamotoNagara Tamaki
Oct 18, 2020·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Keiichiro YoshinagaTohru Shiga

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.